Targeting receptor tyrosine kinase signaling in acute myeloid leukemia.
about
Survey of activated FLT3 signaling in leukemiaDistinct patterns of DNA damage response and apoptosis correlate with Jak/Stat and PI3kinase response profiles in human acute myelogenous leukemiaReconstructing networks of pathways via significance analysis of their intersections.High transcript level of FLT3 associated with high risk of relapse in pediatric acute myeloid leukemia.Dasatinib impairs long-term expansion of leukemic progenitors in a subset of acute myeloid leukemia cases.High-resolution kinetics of cytokine signaling in human CD34/CD117-positive cells in unfractionated bone marrow.Suberoylanilide hydroxamic acid induces hypersensitivity to radiation therapy in acute myelogenous leukemia cells expressing constitutively active FLT3 mutants.Paraptosis cell death induction by the thiamine analog benfotiamine in leukemia cellsA Phase I/II Study of the mTOR Inhibitor Everolimus in Combination with HyperCVAD Chemotherapy in Patients with Relapsed/Refractory Acute Lymphoblastic LeukemiaFavorable clinical outcome and unique characteristics in association with Twist1 overexpression in de novo acute myeloid leukemia.SIRT2 is an unfavorable prognostic biomarker in patients with acute myeloid leukemia.Potential role of sorafenib in the treatment of acute myeloid leukemia.RUNX1 regulates phosphoinositide 3-kinase/AKT pathway: role in chemotherapy sensitivity in acute megakaryocytic leukemia.Buparlisib, a PI3K inhibitor, demonstrates acceptable tolerability and preliminary activity in a phase I trial of patients with advanced leukemias.Oligonucleotide aptamer-drug conjugates for targeted therapy of acute myeloid leukemia.Common leukemia- and lymphoma-associated genetic aberrations in healthy individuals.Targeting C-type lectin-like molecule-1 for antibody-mediated immunotherapy in acute myeloid leukemia.Integrated analysis of proteome, phosphotyrosine-proteome, tyrosine-kinome, and tyrosine-phosphatome in acute myeloid leukemia.Acute myeloid leukemia with the t(8;21) translocation: clinical consequences and biological implications.Monoclonal antibodies against IREM-1: potential for targeted therapy of AML.Feedbacks and adaptive capabilities of the PI3K/Akt/mTOR axis in acute myeloid leukemia revealed by pathway selective inhibition and phosphoproteome analysis.
P2860
Q28477934-E3792472-0CC8-43DA-B914-C14EA739A86CQ28749564-635A55A9-F27C-4812-A99D-0EBF3A8E66C7Q33332005-CADF8FAF-C817-4065-91BA-528FA763C788Q33879678-1A637C13-C3B7-42D8-B107-B663747680DFQ34109861-F6E627BA-C4C0-49BE-A9F3-E7C1D7C6F2A0Q34924515-C38566D9-2C7C-4435-BC5A-519971024070Q35075792-4C313406-0B0A-4C84-97CB-15005095B885Q35596628-E7DFB090-BB02-48B4-A217-AF5C79FD6376Q35752048-2D4072C1-D1F0-4A4F-A348-BE4535793421Q36022536-00DAAF21-C89D-48BB-A684-CBE33E7E950DQ36996528-CD38536E-3A42-4ED8-9EEB-5CB431D71D61Q37340403-1AB90710-523D-4BE1-9241-490C84BBE691Q37372829-67477E9D-D4C7-4E00-8D15-4EE652670CDAQ37715074-560DF266-53A4-475A-A531-6A599FF02E0AQ38850054-0DF3E50B-68FD-40C6-A508-F69DF95A5951Q39585715-70A96C9D-604F-400E-8CB6-1A0D84468AF8Q39817951-C733454D-6AF1-4DC0-81BA-EF55E218BF60Q40956513-559444DA-044B-42BC-A252-4C67A9FEF827Q41973082-5166317E-AE8A-45A3-80D4-310CC1B6C25DQ47805796-EA5618E4-43A2-498D-B3E9-BD9B4E82E2DBQ54362642-12EC635A-5EB5-4E1C-B479-70B33277EF32
P2860
Targeting receptor tyrosine kinase signaling in acute myeloid leukemia.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Targeting receptor tyrosine kinase signaling in acute myeloid leukemia.
@en
type
label
Targeting receptor tyrosine kinase signaling in acute myeloid leukemia.
@en
prefLabel
Targeting receptor tyrosine kinase signaling in acute myeloid leukemia.
@en
P2093
P1476
Targeting receptor tyrosine kinase signaling in acute myeloid leukemia.
@en
P2093
Alexandre Arcaro
Danielle Boller
Kathrin T Doepfner
P304
P356
10.1016/J.CRITREVONC.2007.05.005
P577
2007-07-19T00:00:00Z